NCT06298968View on ClinicalTrials.gov

Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

April 26, 2024

Primary Completion Date

February 25, 2025

Study Completion Date

February 25, 2027

Conditions
Intrahepatic Cholangiocarcinoma
Interventions
DRUG

combined therapy using gemcitabine and cisplatin chemotherapy, Lenvatinib and Adebrelimab

"Gemcitabine (1000mg/m²) and cisplatin (25mg/m²) on day1 and 8 every 3 weeks, with a total of 6 cycles.~Lenvatinib 8 mg once daily (QD) oral dosing, continuous use for 2 years. Adebrelimab 1200mg intravenously every 3 weeks, continuous use for 2 years."

Trial Locations (1)

Unknown

RECRUITING

Nanfang Hospital of Southern Medical University, Guangzhou

All Listed Sponsors
lead

Nanfang Hospital, Southern Medical University

OTHER